NASDAQ · KRYS
Healthcare · Biotechnology
$333.85
Up+$17.03 (+5.10%)
Updated Sep 22, 2026, 9:20 PM
SID Score
6.3/10
Composite research score
Smart Money
62/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
KRYS closed at $333.85 after 20 trading sessions, down 2.30% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 21, 2026 | $339.48 | $341.15 | $332.435 | $333.85 | 210.27K |
| Sep 18, 2026 | $340.00 | $341.35 | $335.50 | $336.67 | 1M |
| Sep 17, 2026 | $340.99 | $343.33 | $335.50 | $338.75 | 280.93K |
| Sep 16, 2026 | $337.53 | $346.20 | $334.7281 | $336.67 | 251.88K |
| Sep 15, 2026 | $339.01 | $340.0899 | $331.7948 | $336.68 | 225.82K |
| Sep 14, 2026 | $349.14 | $352.545 | $339.25 | $340.03 | 288.54K |
| Sep 11, 2026 | $349.59 | $354.2404 | $346.68 | $347.00 | 206.32K |
| Sep 10, 2026 | $347.56 | $349.655 | $344.26 | $345.55 | 175.79K |
| Sep 9, 2026 | $348.85 | $353.115 | $340.175 | $348.09 | 222.38K |
| Sep 8, 2026 | $350.49 | $354.6877 | $343.46 | $351.26 | 255.88K |
| Sep 4, 2026 | $365.45 | $371.99 | $353.745 | $358.24 | 323.02K |
| Sep 3, 2026 | $371.41 | $373.31 | $365.555 | $371.47 | 226.49K |
| Sep 2, 2026 | $366.00 | $373.19 | $360.86 | $369.23 | 305.2K |
| Sep 1, 2026 | $360.00 | $364.44 | $358.38 | $363.84 | 197.43K |
| Aug 31, 2026 | $348.62 | $363.52 | $345.14 | $359.36 | 222.78K |
| Aug 28, 2026 | $356.92 | $356.92 | $348.57 | $351.46 | 143.51K |
| Aug 27, 2026 | $357.61 | $362.50 | $355.09 | $357.46 | 181.43K |
| Aug 26, 2026 | $354.37 | $363.82 | $350.43 | $359.76 | 281.03K |
| Aug 25, 2026 | $343.81 | $357.91 | $343.81 | $356.19 | 205.05K |
| Aug 24, 2026 | $343.51 | $346.5499 | $337.09 | $341.72 | 236.71K |
The latest Smart Investors Daily articles mentioning KRYS.
KRYS research
Company profile and research snapshot.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | B of A Securities | Buy | — |
| Aug 14, 2026 | RBC Capital | Outperform | — |
| Aug 4, 2026 | Citigroup | Buy | — |
| Jul 14, 2026 | B of A Securities | Buy | — |
| Jun 18, 2026 | TD Cowen | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 10, 2026
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.48% on an annualized basis producing an average annual return of 43.76%. Currently, Krystal Biotech has a market capitalization of
Yahoo · Sep 3, 2026
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo · Sep 3, 2026
PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 3:55 pm ET on Thursday, September 10, 2026 and will be posted on the Investors secti
Yahoo · Sep 2, 2026
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KRYS.
